How to Get Semaglutide (Wegovy) through the Medicare GLP-1 Bridge Program
If you are a Medicare beneficiary, you can now access GLP-1 weight loss medications, including semaglutide (Wegovy), for just $50 a month via a new federal program called the Medicare GLP-1 Bridge. The program started July 1, 2026, and will run through December 31, 2027.
The Medicare GLP-1 Bridge requires Medicare Part D enrollment, meeting eligibility requirements, and getting prior authorization from CMS. The process includes several steps involving your doctor, your insurance plan, and a centralized CMS processor. Without the right help, you can easily become stuck or delayed.
In this guide, we'll explain how to get semaglutide through the Medicare GLP-1 Bridge Program and how NP2GO can help simplify the application process from start to finish.
What Is the Medicare GLP-1 Bridge Program?
The Medicare GLP-1 Bridge Program is a temporary initiative by the Centers for Medicare & Medicaid Services (CMS) that allows eligible Medicare Part D beneficiaries to access certain FDA-approved GLP-1 weight-loss medications at a fixed monthly cost of $50. The program was launched on July 1, 2026, and is scheduled to run through December 31, 2027.
Because the Medicare GLP-1 Bridge Program operates as a distinct demonstration project on its own track, it uses a single centralized processor managed by CMS to handle prior authorizations, claims processing, and pharmacy reimbursements. This means your regular Part D plan does not manage prescriptions, review prior authorizations, or cover any program costs.
The program currently includes the following GLP-1 medications for weight management:
Wegovy (semaglutide) — both the injectable pen and oral tablet formulations.
Zepbound KwikPen (tirzepatide).
Foundayo pill formulation.
The Bridge Program is available in all 50 states and U.S. territories.
When the current Bridge demonstration ends, CMS intends to transition toward a longer-term model called the BALANCE Model.
Step-by-Step: How to Get Semaglutide (Wegovy) Through the Medicare Bridge Program
To get semaglutide (Wegovy) through the Medicare GLP-1 Bridge program, follow these steps:
Step 1: Confirm Part D coverage
The first step is to confirm you are enrolled in a stand-alone Part D plan or a Medicare Advantage plan that includes drug coverage.
For the CMS Medicare GLP-1 Bridge, eligible beneficiaries must be enrolled in one of the following:
A standalone Medicare Part D Prescription Drug Plan (PDP)
A Medicare Advantage Prescription Drug (MA-PD) plan
A Special Needs Plan (SNP) that includes prescription drug coverage
The Limited Income Newly Eligible Transition (LI NET) program
An eligible Employer Group Waiver Plan (EGWP)
However, some Medicare plan types are not eligible to participate in the Bridge Program on their own. For example, if you’re enrolled in a Private Fee-for-Service (PFFS) plan, a Section 1876 Cost Plan, or a Program of All-Inclusive Care for the Elderly (PACE) organization, you may not qualify unless you are also enrolled in a standalone Medicare Part D Prescription Drug Plan.
You do not require the Bridge program if your GLP-1 medicine is already covered by regular Medicare Part D, such as if you have type 2 diabetes, moderate-to-severe obstructive sleep apnea, or established cardiovascular disease. Your usual Part D plan will continue to handle your medication.
If you're unsure whether your Medicare plan qualifies, our healthcare provider at NP2GO can help verify your eligibility before you move forward.
Step 2: Medical evaluation
Before prescribing semaglutide, your healthcare provider will perform a comprehensive medical evaluation to determine whether the medication is appropriate for you.
Your provider will:
Review your medical history, previous weight-loss attempts, and current lifestyle habits.
Calculate your Body Mass Index (BMI) and document any qualifying comorbidities.
Order baseline labs (e.g., CMP, lipid panel, HbA1c, TSH, and pregnancy test if applicable).
Confirm the medication is being prescribed as part of a comprehensive plan that includes nutrition, physical activity, and behavioral support.
You may qualify if you:
Have a BMI of 35 or higher, or
Have a BMI of 30 or higher with a diagnosis of one or more of these conditions: uncontrolled hypertension, diastolic heart failure, or chronic kidney disease Stage 3a or higher, or
Have a BMI of 27 or higher along with at least one qualifying obesity-related health condition, such as:
Cardiovascular disease or a history of stroke
Prediabetes
Hypertension that remains uncontrolled despite treatment
Advanced kidney disease
Heart failure
The Medicare GLP-1 Bridge Program is intended for people who are at increased metabolic or cardiovascular risk, so your healthcare provider will need to document that you meet the applicable medical criteria when submitting your request.
Step 3: Get a Wegovy prescription
If you meet the clinical criteria, your provider will prescribe an approved drug under the program—most commonly Wegovy (semaglutide) in injectable pen or tablet form, or other covered options like Zepbound KwikPen or Foundayo, depending on your needs and availability.
Step 4: Provider submits prior authorization
Your provider must submit a specific prior authorization form along with supporting clinical documentation directly to the CMS central processor, not to your Part D plan.
Required elements include attestation of eligibility criteria, BMI documentation, relevant diagnoses, and confirmation of lifestyle counseling. Submission is usually done electronically or via fax.
Many medical offices may have limited initial experience with this new centralized submission process, which can lead to delays.
At NP2GO, our clinicians are experienced with the requirements of the Medicare GLP-1 Bridge Program. We handle documentation, form completion, and submission efficiently, minimizing back-and-forth and speeding up approvals for our patients.
Step 5: Get approved
Once submitted, the central processor reviews the request. Approvals may come within days to a couple of weeks, though initial rollout periods could see longer wait times due to volume.
You and/or your provider should receive notification of PA approval or denial in the mail. If denied, your provider can appeal with additional evidence or explore alternative coverage.
Step 6: Fill your prescription
Fill your prescription at your pharmacy and pay a $50 copayment for a one-month supply. To get a refill, you don’t need a new approval as long as you stay on semaglutide, even if your dose increases.
Step 7: Ongoing monitoring and refills.
Continue working with your healthcare provider to monitor your progress, manage any side effects, and determine whether dosage adjustments are needed.
Which Forms of Wegovy Are Included in the Medicare GLP-1 Bridge Program?
The Medicare GLP-1 Bridge Program covers both forms of Wegovy (semaglutide) for eligible beneficiaries:
The once-weekly injectable pen, and
The daily oral tablet (pill).
Whichever form you and your clinician choose, the $50 monthly copay remains the same under the Bridge Program.
Although both medications contain the same active ingredient, semaglutide, they differ in how they are taken. Wegovy injections are administered once weekly, while the oral formulation is taken once daily. Both work by mimicking the GLP-1 hormone to reduce appetite, increase feelings of fullness, slow stomach emptying, and help regulate blood sugar levels.
If you qualify for the Medicare GLP-1 Bridge Program, both the Wegovy injection and the pill are covered with a $50 monthly copay when prescribed specifically for chronic weight management.
However, if your clinician prescribes semaglutide primarily for other indications, such as cardiovascular risk reduction or MASH (metabolic dysfunction-associated steatohepatitis), the prescription may instead process through your standard Medicare Part D plan rather than the Bridge Program.
How Much Does Wegovy Cost with the Medicare GLP-1 Bridge Program?
If approved for the Medicare GLP-1 Bridge Program, you will pay a fixed $50 copayment per month at the pharmacy when filling your Wegovy prescription. The program covers the remaining cost of the medication.
This $50 monthly copay applies to a standard one-month supply (28 or 30 days, depending on the formulation) and is the same whether you use the injectable pen or the oral tablet.
Because the Bridge Program operates as a separate demonstration from standard Medicare Part D, the $50 monthly payment does not count toward your Part D deductible or annual out-of-pocket maximum.
FAQs About How to Get Semaglutide (Wegovy) Through the Medicare GLP-1 Bridge Program
How do I get semaglutide covered by the Medicare GLP-1 Bridge Program?
Semaglutide (Wegovy) can be covered under the Medicare GLP-1 Bridge Program for eligible Part D beneficiaries at $50/month. To get it covered, you need to confirm your Part D coverage, see a provider for a full evaluation, prescription, and documentation, then have them submit a prior authorization to the CMS central processor.
Who qualifies for the Medicare Bridge Program?
You must have Medicare Part D coverage, be 18+, and need the medication for chronic weight management. Qualification depends on BMI tiers: 35 or higher (BMI alone), 30 or higher, or 27 or higher with specific comorbidities such as heart failure, prediabetes, hypertension, heart attack, or stroke. Your healthcare provider must also document the criteria and submit prior authorization.
Can Medicare patients get Wegovy?
Yes. Eligible Medicare patients with Part D coverage can access Wegovy for $50 per month through the Medicare GLP-1 Bridge Program if they meet BMI and clinical criteria. The program covers both Wegovy injection and oral formulations for weight management.
How long does the Medicare Bridge Program last?
The Medicare GLP-1 Bridge Program runs from July 1, 2026, through December 31, 2027. During this period, eligible beneficiaries can access covered GLP-1 medications, such as Wegovy, at a $50/month cost. After 2027, coverage will depend on future CMS decisions.
How to apply for the Medicare GLP-1 Bridge Program?
To apply for the Medicare GLP-1 program, confirm Part D coverage, undergo a medical evaluation with a provider to confirm BMI and eligibility, then have your provider submit a prior authorization request with documentation to the CMS central processor. Once approved, fill your prescription at a pharmacy for the $50 copay.
How to get Wegovy if the Medicare GLP-1 Bridge Program won't cover it?
If ineligible for the Bridge, options include paying out of pocket, using manufacturer savings cards, exploring compounded semaglutide through reputable clinics like NP2GO, or checking for alternative coverage, like diabetes or cardiovascular indications under standard Part D.
Is the Medicare GLP-1 Bridge Program free?
No. The program is not free. Eligible beneficiaries pay a $50 monthly copayment for a one-month supply of covered GLP-1 medications, such as Wegovy. Additional costs may include doctor visits and lab work.
How NP2GO Can Help
Getting semaglutide (Wegovy) through the Medicare GLP-1 Bridge Program involves several steps, including confirming your eligibility and completing a medical evaluation, submitting prior authorization requests, and providing supporting documentation. However, the process may come with challenges because the system is new, and making a mistake could cause a major delay in access.
At NP2GO, our providers are well-versed in preparing and submitting prior authorization requests for the Medicare GLP-1 Bridge Program. We help gather the required medical documentation, complete the necessary paperwork, and coordinate everything throughout the review process whenever additional information is needed.
We offer telehealth appointments across 38 states, including Oklahoma, California, Idaho, Connecticut, and Washington, D.C., allowing you to consult with an experienced healthcare provider from the comfort of your home.
If you're interested in learning whether you qualify for semaglutide through the Medicare GLP-1 Bridge Program, schedule a consultation with NP2GO today to learn more about your treatment options and receive personalized support in navigating the program.
